JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

40.23 -6.29

Overview

Share price change

24h

Current

Min

40.23

Max

42.91

Key metrics

By Trading Economics

Income

-19M

-116M

Sales

670K

1M

Profit margin

-11,216.004

Employees

437

EBITDA

-19M

-129M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+99.36% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

1.4B

4B

Previous open

46.52

Previous close

40.23

News Sentiment

By Acuity

50%

50%

168 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Oct 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 Oct 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 Oct 2025, 21:20 UTC

Earnings

Correction to IBM 3Q Sales Jump Article

22 Oct 2025, 20:57 UTC

Earnings

SAP Posts Higher 3Q Revenue, Operating Profit

22 Oct 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 Oct 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 Oct 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 Oct 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 Oct 2025, 23:15 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 Oct 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 Oct 2025, 22:02 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 Oct 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 Oct 2025, 21:58 UTC

Acquisitions, Mergers, Takeovers

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 Oct 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 Oct 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 Oct 2025, 21:47 UTC

Acquisitions, Mergers, Takeovers

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 Oct 2025, 21:47 UTC

Earnings

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 Oct 2025, 21:47 UTC

Acquisitions, Mergers, Takeovers

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 Oct 2025, 21:46 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 Oct 2025, 21:28 UTC

Market Talk
Earnings

Correction to Alcoa Tariff Market Talk

22 Oct 2025, 21:25 UTC

Earnings

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 Oct 2025, 21:17 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 Oct 2025, 21:09 UTC

Market Talk
Earnings

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 Oct 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 Oct 2025, 20:59 UTC

Earnings

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 Oct 2025, 20:51 UTC

Earnings

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 Oct 2025, 20:44 UTC

Earnings

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

99.36% upside

12 Months Forecast

Average 80.6 USD  99.36%

High 143 USD

Low 40 USD

Based on 16 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

168 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat